Navigation Links
Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
Date:9/16/2008

GENEVA, Sept. 17 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment has been completed in the REFLEX trial (Rebif FLEXible dosing in early multiple sclerosis). This randomized, double-blind, placebo-controlled, international Phase III trial is designed to evaluate the therapeutic benefit of Rebif(R) (interferon beta-1a) on the time to conversion to multiple sclerosis (MS) in people with a first clinical event suggestive of the disease.

"It has been demonstrated that treatment with interferon beta can reduce the risk of developing multiple sclerosis," said Anton Hoos, Executive Vice President, Global Development, Merck Serono. "However, additional research still needs to be conducted in this area and we believe the REFLEX study will provide valuable insights."

A total of 517 patients considered at risk of developing MS due to a recently experienced isolated demyelinating event (e.g. optic neuritis, myelopathy or brainstem syndrome) and having magnetic resonance imaging (MRI) brain scans consistent with early signs of MS have been enrolled in the REFLEX trial. Study participants were randomized in a 1:1:1 ratio to receive either Rebif(R) 44 micrograms three times a week, Rebif(R) 44 micrograms once a week, or placebo as a subcutaneous injection. Patients will be treated for a period of 24 months, or up to the time when they experience a second attack leading to a diagnosis of clinically definite MS. At this point, patients are offered open-label treatment with Rebif(R) 44 micrograms three times a week.

The primary endpoint of the REFLEX trial is time to conversion to MS, according to the McDonald criteria. Further endpoints include time to conversion to clinically definite MS (the main secondary endpoint), assessments of MRI brain scans, clinical relapses and disability progression.

Rebif(R) is currently approved for the treatment of relapsing forms of MS. It has been p
'/>"/>

SOURCE Merck Serono International S A
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
2. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
3. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
8. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
9. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
10. Merck/Gilead Once-A-Day AIDS Pill Not Available in Most Places - AHF Urges Speed-Up of Registrations
11. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
(Date:1/23/2015)... 2015 Gem Pharmaceuticals announced today that the initial ... the Company,s Phase 2 clinical trial.  This open-label study ... compound, GPX-150 (an investigational medication), in approximately 30 adults ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/23/2015)... China , Jan. 23, 2015 Tianyin Pharmaceutical ... company that specializes in the development and sale of ... generics and active pharmaceutical ingredients (API) today announced the ... (JCM) API operation. 1. Following the September ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... 2, 2011 Naviscan, Inc., announces the European ... scanner at two prestigious radiology conferences in Vienna. ... Breast Imaging (EUSOBI) Annual Scientific Meeting, a podium ... Emission Mammography) data demonstrating PEM,s ability to reduce ...
... (Nasdaq: PCYC ) today announced that further ... anti-arthritis activity in mice and rats, has been suspended ... studies.  The company hopes to have a new clinical ... PCI-45292 has been under preclinical development for approximately ...
Cached Medicine Technology:Naviscan Announces European Launch of Positron Emission Mammography 2Update on Preclinical Finding and Development Timeline for PCI-45292 2Update on Preclinical Finding and Development Timeline for PCI-45292 3
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... JJsHouse.com is a famous dress online store ... announces its latest collection of wedding dresses , and ... issue is the wedding dress on your big day; the ... life. Every bride wants to find the most suitable wedding ...
(Date:1/22/2015)... Richmond, VA (PRWEB) January 22, 2015 ... the power at the Science Museum of Virginia. Wicked ... 24. , Wicked Plants unearths 75 poisonous, carnivorous and ... traverse through each room to uncover the biochemical, physical ...
(Date:12/26/2014)... said that nothing makes a lady feel more feminine than ... shows its new selection of navy cocktail dresses , ... navy cocktail gowns are the cornerstones of the site’s cocktail ... dresses in bright neon colors can be dressed up or ...
Breaking Medicine News(10 mins):Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2
... TeamStaff, Inc. (Nasdaq: TSTF) , a national provider of ... Company has completed an in-depth strategic review of its businesses ... and changing dynamics in the healthcare market. The analysis ... the board of directors and the executive management team led ...
... , DALLAS, Nov. 3 IBM ... of its Health Analytics Solution Center, part of a ... needed to help hospitals and medical staff improve decision-making and provide ... ) , The center will be hosted in the IBM Global ...
... Nov. 3 HealthSouth Corporation (NYSE: HLS ) today ... September 30, 2009. The results showed consolidated net operating revenues ... to $455.5 million for the third quarter of 2008, or ... a 5.3% quarter-over-quarter increase in patient discharges on both a ...
... Democratic Senators Tom Harkin and Mary Landrieu and Congresswoman ... from Des Moines, Iowa; Gwendolyn Barnes, a small business ... business owner from Richmond, Virginia; and other small business ... this morning to discuss how health insurance reform will ...
... The American Society of Hematology (ASH) is honoring two prominent ... role they play in the training and career development of ... Arthur W. Nienhuis, MD, will receive their awards during the ... who will be receiving the Mentor Award for Basic Science, ...
... Four researchers from Thomas Jefferson University have received $3.9 ... American Recovery and Reinvestment Act. The NIH has ... for this new initiative called the Challenge Grants in ... across the country have been funded. This program supports ...
Cached Medicine News:Health News:TeamStaff Announces Revised Business Strategy; Chief Executive Officer to Step Down on Completion of Search For Successor 2Health News:TeamStaff Announces Revised Business Strategy; Chief Executive Officer to Step Down on Completion of Search For Successor 3Health News:IBM Launches Health Analytics Center 2Health News:IBM Launches Health Analytics Center 3Health News:IBM Launches Health Analytics Center 4Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 2Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 3Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 4Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 5Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 6Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 7Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 8Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 9Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 10Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 11Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 12Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 13Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 14Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 15Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 16Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 17Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 18Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 19Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 20Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 21Health News:HealthSouth Reports Strong Results for Third Quarter 2009 and Increases 2009 Guidance 22Health News:Democratic Senators, Congresswoman, Small Business Owners Discuss Impact of Health Insurance Reform on Small Businesses 2Health News:Democratic Senators, Congresswoman, Small Business Owners Discuss Impact of Health Insurance Reform on Small Businesses 3Health News:The American Society of Hematology to honor inspirational hematologists with Mentor Awards 2Health News:Jefferson researchers receive $3.9 million in Challenge grants 2Health News:Jefferson researchers receive $3.9 million in Challenge grants 3
Heine Beta 200 Streak Retinoscope 2.5v...
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option....
System, English (Continental cord), 230 VAC....
Micro-mini fiber optic light....
Medicine Products: